These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 31478399)

  • 1. Osimertinib in first-line treatment of advanced EGFR-mutated non-small-cell lung cancer: a cost-effectiveness analysis.
    Aguilar-Serra J; Gimeno-Ballester V; Pastor-Clerigues A; Milara J; Marti-Bonmati E; Trigo-Vicente C; Alós-Almiñana M; Cortijo J
    J Comp Eff Res; 2019 Aug; 8(11):853-863. PubMed ID: 31478399
    [No Abstract]   [Full Text] [Related]  

  • 2. Cost-effectiveness analysis of osimertinib for first-line treatment of locally advanced or metastatic EGFR mutation positive non-small cell lung cancer in Singapore.
    Aziz MIA; Foo WYX; Toh CK; Lim WT; Ng K
    J Med Econ; 2020 Nov; 23(11):1330-1339. PubMed ID: 32886557
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness analysis of first-line treatments for advanced epidermal growth factor receptor-mutant non-small cell lung cancer patients.
    Li WQ; Li LY; Chai J; Cui JW
    Cancer Med; 2021 Mar; 10(6):1964-1974. PubMed ID: 33626238
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of Osimertinib as First-line Treatment and Sequential Therapy for EGFR Mutation-positive Non-small Cell Lung Cancer in China.
    Cai H; Zhang L; Li N; Chen S; Zheng B; Yang J; Weng L; Liu MB
    Clin Ther; 2019 Feb; 41(2):280-290. PubMed ID: 30639208
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Economic analysis of osimertinib in previously untreated EGFR-mutant advanced non-small cell lung cancer in Canada.
    Ezeife DA; Kirk V; Chew DS; Nixon NA; Lee R; Le LW; Chan KK; Leighl NB
    Lung Cancer; 2018 Nov; 125():1-7. PubMed ID: 30429004
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of osimertinib versus standard EGFR-TKI as first-line treatment for locally advanced or metastatic EGFR mutation-positive non-small cell lung cancer in Australia.
    Khoo T; Gao L
    Expert Rev Pharmacoecon Outcomes Res; 2021 Jun; 21(3):415-423. PubMed ID: 33151783
    [No Abstract]   [Full Text] [Related]  

  • 7. Cost-effectiveness of Osimertinib as a Second-line Treatment in Patients With EGFR-mutated Advanced Non-Small Cell Lung Cancer in China.
    Guan H; Liu G; Xie F; Sheng Y; Shi L
    Clin Ther; 2019 Nov; 41(11):2308-2320.e11. PubMed ID: 31607559
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness analysis of the first-line EGFR-TKIs in patients with non-small cell lung cancer harbouring EGFR mutations.
    Holleman MS; Al MJ; Zaim R; Groen HJM; Uyl-de Groot CA
    Eur J Health Econ; 2020 Feb; 21(1):153-164. PubMed ID: 31541309
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-Effectiveness of Osimertinib in Treating Newly Diagnosed, Advanced EGFR-Mutation-Positive Non-Small Cell Lung Cancer.
    Wu B; Gu X; Zhang Q; Xie F
    Oncologist; 2019 Mar; 24(3):349-357. PubMed ID: 30257889
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Osimertinib in Patients With Treatment-Naive EGFR-Mutant Non-small Cell Lung Cancer: Overall Survival, Post-progression Management and Budget Impact Analysis in Real-World.
    Pasello G; Lorenzi M; Scattolin D; Del Conte A; Cecere F; Pavan A; Macerelli M; Polo V; Pilotto S; Santarpia M; Cumerlato E; Da Ros V; Targato G; Bortolami A; Bonanno L; Ferro A; Dal Maso A; Frega S; Guarneri V
    Oncologist; 2024 Jul; 29(7):596-608. PubMed ID: 38520745
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of Osimertinib in the First-Line Treatment of Patients With EGFR-Mutated Advanced Non-Small Cell Lung Cancer.
    Aguiar PN; Haaland B; Park W; San Tan P; Del Giglio A; de Lima Lopes G
    JAMA Oncol; 2018 Aug; 4(8):1080-1084. PubMed ID: 29852038
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.
    Soria JC; Ohe Y; Vansteenkiste J; Reungwetwattana T; Chewaskulyong B; Lee KH; Dechaphunkul A; Imamura F; Nogami N; Kurata T; Okamoto I; Zhou C; Cho BC; Cheng Y; Cho EK; Voon PJ; Planchard D; Su WC; Gray JE; Lee SM; Hodge R; Marotti M; Rukazenkov Y; Ramalingam SS;
    N Engl J Med; 2018 Jan; 378(2):113-125. PubMed ID: 29151359
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Overall Survival with Osimertinib in Untreated,
    Ramalingam SS; Vansteenkiste J; Planchard D; Cho BC; Gray JE; Ohe Y; Zhou C; Reungwetwattana T; Cheng Y; Chewaskulyong B; Shah R; Cobo M; Lee KH; Cheema P; Tiseo M; John T; Lin MC; Imamura F; Kurata T; Todd A; Hodge R; Saggese M; Rukazenkov Y; Soria JC;
    N Engl J Med; 2020 Jan; 382(1):41-50. PubMed ID: 31751012
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of Osimertinib vs Docetaxel-bevacizumab in Third-line Treatment in EGFR T790M Resistance Mutation Advanced Non-Small Cell Lung Cancer in China.
    Rui M; Li H
    Clin Ther; 2020 Nov; 42(11):2159-2170.e6. PubMed ID: 33028495
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of osimertinib in the UK for advanced EGFR-T790M non-small cell lung cancer.
    Bertranou E; Bodnar C; Dansk V; Greystoke A; Large S; Dyer M
    J Med Econ; 2018 Feb; 21(2):113-121. PubMed ID: 28880737
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incremental cost-effectiveness analysis of tyrosine kinase inhibitors in advanced non-small cell lung cancer with mutations of the epidermal growth factor receptor in Colombia.
    Lasalvia P; Hernández F; Gil-Rojas Y; Rosselli D
    Expert Rev Pharmacoecon Outcomes Res; 2021 Aug; 21(4):821-827. PubMed ID: 32498573
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness analysis of the first-line EGFR-TKIs in patients with advanced EGFR-mutated non-small-cell lung cancer.
    Aguilar-Serra J; Gimeno-Ballester V; Pastor-Clerigues A; Milara J; Trigo-Vicente C; Cortijo J
    Expert Rev Pharmacoecon Outcomes Res; 2022 Jun; 22(4):637-646. PubMed ID: 34602008
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-Effectiveness of Osimertinib for EGFR Mutation-Positive Non-Small Cell Lung Cancer after Progression following First-Line EGFR TKI Therapy.
    Wu B; Gu X; Zhang Q
    J Thorac Oncol; 2018 Feb; 13(2):184-193. PubMed ID: 29101057
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modeling the Cost-Effectiveness of Adjuvant Osimertinib for Patients with Resected EGFR-mutant Non-Small Cell Lung Cancer.
    Lemmon CA; Zabor EC; Pennell NA
    Oncologist; 2022 May; 27(5):407-413. PubMed ID: 35285487
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Budget impact of sequential treatment with first-line afatinib versus first-line osimertinib in non-small-cell lung cancer patients with common EGFR mutations.
    Westerink L; Nicolai JLJ; Samuelsen C; Smit HJM; Postmus PE; Griebsch I; Postma MJ
    Eur J Health Econ; 2020 Aug; 21(6):931-943. PubMed ID: 32328874
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.